转移性非小细胞肺癌的治疗综述：一种实用方法
Review of the treatment of metastatic non small cell lung carcinoma: A practical approach.
作者信息
Hirsh Vera
机构信息
Vera Hirsh, Department of Medical Oncology, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC H3A 1A1, Canada.
出版信息
World J Clin Oncol. 2011 Jun 10;2(6):262-71. doi: 10.5306/wjco.v2.i6.262.
Abstract
In recent years, as we have a better knowledge and understanding of the biology of non small cell lung carcinoma (NSCLC), which leads us to targeting biomarkers driving the NSCLC carcinogenesis and metastatic potential, we now have an increased number of options to offer our patients with NSCLC. We also realize the importance of distinguishing squamous and non squamous histology to guide our treatment decisions of NSCLC. The palliative care concomitant with therapies from the very start of the treatment also showed an impact on survival. This review examines the treatment options in all lines of therapy for metastatic NSCLC that have been approved in Canada, the United States, or Europe.
摘要
近年来，随着我们对非小细胞肺癌（NSCLC）生物学有了更深入的认识和理解，这使我们能够针对驱动NSCLC致癌作用和转移潜能的生物标志物，现在我们为NSCLC患者提供了更多的选择。我们也认识到区分鳞状和非鳞状组织学对于指导NSCLC治疗决策的重要性。从治疗一开始就与治疗同时进行的姑息治疗也显示出对生存的影响。本综述探讨了在加拿大、美国或欧洲已获批的转移性NSCLC各线治疗中的治疗选择。
相似文献
1
Review of the treatment of metastatic non small cell lung carcinoma: A practical approach.转移性非小细胞肺癌的治疗综述：一种实用方法
World J Clin Oncol. 2011 Jun 10;2(6):262-71. doi: 10.5306/wjco.v2.i6.262.
2
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.表皮生长因子受体抑制在肺癌鳞状细胞癌治疗中的应用
Oncologist. 2016 Feb;21(2):205-13. doi: 10.1634/theoncologist.2015-0209. Epub 2016 Jan 14.
3
4
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.促进抗 PD-1 治疗的疗效：纳武利尤单抗联合放疗治疗晚期非小细胞肺癌 - FORCE 试验研究方案。
BMC Cancer. 2019 Nov 8;19(1):1074. doi: 10.1186/s12885-019-6205-0.
5
Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.转移性非小细胞肺癌的系统治疗，重点是靶向治疗：合理的方法。
Curr Oncol. 2010 Apr;17(2):13-23. doi: 10.3747/co.v17i2.549.
6
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.一线化疗治疗成人局部晚期或转移性非小细胞肺癌的临床效果和成本效益：系统评价和经济评估。
Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310.
7
[Effect of Erlotinib in 2nd and 3rd Line Anticancer Treatment in Patients with Squamous Cell Lung Cancer - Case Series].[厄洛替尼在鳞状细胞肺癌患者二线及三线抗癌治疗中的疗效——病例系列]
Klin Onkol. 2017 Spring;30(2):131-135. doi: 10.14735/amko2017131.
8
Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.美国医疗保险转移性鳞状非小细胞肺癌患者的真实世界治疗模式和费用。
Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002. Epub 2014 Nov 8.
9
[Non-small cell lung cancer. New biomarkers for diagnostics and therapy].[非小细胞肺癌。用于诊断和治疗的新型生物标志物]
Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1.
10
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.1990 - 2015年美国转移性非小细胞肺癌一线全身治疗的生存获益：进展与机遇
Oncologist. 2017 Mar;22(3):304-310. doi: 10.1634/theoncologist.2016-0253. Epub 2017 Feb 27.
引用本文的文献
1
Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis.评估聚（ADP-核糖）聚合酶（PARP）抑制剂用于晚期肺癌治疗的获益和安全性概况：一项全面的系统评价和荟萃分析。
Front Pharmacol. 2024 Jun 21;15:1338442. doi: 10.3389/fphar.2024.1338442. eCollection 2024.
2
Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis.纳米给药在非小细胞肺癌治疗中的有效性和安全性在一定程度上良好：一项系统评价和荟萃分析
J Oncol. 2022 Mar 8;2022:9017198. doi: 10.1155/2022/9017198. eCollection 2022.
3
Reviving up dendritic cells can run cancer immune wheel in non-small cell lung cancer: a prospective two-arm study.激活树突状细胞可使非小细胞肺癌的肿瘤免疫循环运转：一项前瞻性双臂研究。
Cancer Immunol Immunother. 2021 Mar;70(3):733-742. doi: 10.1007/s00262-020-02704-7. Epub 2020 Sep 12.
4
Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer.树突状细胞疫苗联合细胞因子诱导的杀伤细胞疗法治疗晚期非小细胞肺癌
Oncol Lett. 2016 Apr;11(4):2605-2610. doi: 10.3892/ol.2016.4273. Epub 2016 Feb 24.
5
Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.细胞核存活素表达：晚期非小细胞肺癌患者对紫杉烷-铂类化疗反应的一个预后因素。
Med Oncol. 2014 Aug;31(8):79. doi: 10.1007/s12032-014-0079-4. Epub 2014 Jun 25.
6
Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy.组织学作为预测晚期非小细胞肺癌接受长春瑞滨和丝裂霉素联合化疗患者预后的潜在临床指标。
Lung. 2013 Jun;191(3):271-80. doi: 10.1007/s00408-013-9458-4. Epub 2013 Apr 7.
本文引用的文献
1
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.ATLAS：一项随机、双盲、安慰剂对照的 IIIB 期临床试验，比较贝伐珠单抗联合或不联合厄洛替尼治疗与贝伐珠单抗单药一线治疗晚期非小细胞肺癌的疗效，化疗后完成。
J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.
2
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).凡德他尼与安慰剂在表皮生长因子受体酪氨酸激酶抑制剂治疗后进展的晚期非小细胞肺癌患者中的比较：一项随机、双盲 III 期试验（ZEPHYR）。
J Clin Oncol. 2012 Apr 1;30(10):1114-21. doi: 10.1200/JCO.2011.36.1709. Epub 2012 Feb 27.
3
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.凡德他尼联合培美曲塞二线治疗晚期非小细胞肺癌的随机、双盲 III 期临床试验
J Clin Oncol. 2011 Mar 10;29(8):1067-74. doi: 10.1200/JCO.2010.29.5717. Epub 2011 Jan 31.
4
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
5
Screening for epidermal growth factor receptor mutations in lung cancer.肺癌中表皮生长因子受体突变的筛查
N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.
6
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
7
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.点破研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐珠单抗联合治疗继以培美曲塞/贝伐珠单抗维持治疗与紫杉醇/卡铂/贝伐珠单抗联合治疗继以贝伐珠单抗维持治疗用于 IIIB 或 IV 期非鳞状非小细胞肺癌患者的随机、开放标签 III 期研究。
Clin Lung Cancer. 2009 Jul;10(4):252-6. doi: 10.3816/CLC.2009.n.035.
8
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.挪威肺癌研究小组的III期研究：培美曲塞联合卡铂与吉西他滨联合卡铂作为晚期非小细胞肺癌一线化疗的比较
J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.
9
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.西妥昔单抗联合化疗治疗晚期非小细胞肺癌患者（FLEX）：一项开放标签的随机III期试验。
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
10
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?晚期非小细胞肺癌一线化疗后的潜在治疗选择：维持治疗还是早期二线治疗？
Oncologist. 2009 Feb;14(2):137-47. doi: 10.1634/theoncologist.2008-0152. Epub 2009 Feb 3.
Zotero 插件